Macrocure (MCUR) vs. Its Peers Financial Analysis

Macrocure (NASDAQ: MCUR) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Macrocure to related companies based on the strength of its analyst recommendations, earnings, risk, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Macrocure and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Macrocure N/A -24.50% -22.85%
Macrocure Competitors -540.60% -41.61% -24.68%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Macrocure and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Macrocure 0 0 0 0 N/A
Macrocure Competitors 67 311 960 27 2.69

As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 26.26%. Given Macrocure’s rivals higher probable upside, analysts clearly believe Macrocure has less favorable growth aspects than its rivals.

Risk and Volatility

Macrocure has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Macrocure’s rivals have a beta of 0.89, meaning that their average share price is 11% less volatile than the S&P 500.

Insider and Institutional Ownership

2.8% of Macrocure shares are held by institutional investors. Comparatively, 66.8% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Macrocure and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Macrocure N/A N/A -0.79
Macrocure Competitors $2.40 billion $905.93 million 0.06

Macrocure’s rivals have higher revenue and earnings than Macrocure. Macrocure is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Macrocure rivals beat Macrocure on 5 of the 8 factors compared.

About Macrocure

Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body’s natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.

Receive News & Ratings for Macrocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Macrocure Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply